nucleofection is a highly effective gene transfertechnique for human melanoma cell lines
DESCRIPTION
Despite the increasing use of gene transfer strategies in the study of cellular and molecular biology, melanoma cells have remained difficult to transfect in a safe, efficient, and reproducible manner. In the present study, we report the successful use of nucleofector technology to transfect human melanoma cell lines.TRANSCRIPT
Nucleofection is a highly effective gene transfertechnique for human melanoma cell lines
Sandra Y. Han1*, Weiming Gai1*, Molly Yancovitz1, Iman Osman1, Charles J. Di Como2
and David Polsky1
1Department of Dermatology, New York Harbor Healthcare System, New York University School of Medicine, New York, NY, USA;2Aureon Laboratories, Inc., Yonkers, NY, USA
Correspondence: David Polsky, MD, PhD, Department of Dermatology, NYU School of Medicine, 522 First Avenue, Rm. 401, New York, NY
10016, USA, Tel.: +212 263 9087, Fax: +212 263 5819, e-mail: [email protected]
*Sandra Y. Han and Weiming Gai contributed equally to this study.
Sources of Support: Department of Veteran Affairs Medical Research Service.
Accepted for publication 13 December 2007
Abstract: Despite the increasing use of gene transfer strategies in
the study of cellular and molecular biology, melanoma cells have
remained difficult to transfect in a safe, efficient, and reproducible
manner. In the present study, we report the successful use of
nucleofector technology to transfect human melanoma cell lines.
This technology uses an empirically derived combination of cell
line-specific solutions and nucleofector programmes to
electroporate nucleic acid substrates directly into the cell nucleus.
Using a colorimetric b-galactosidase assay, we optimized
nucleofection parameters for 13 melanoma cell lines, leading to
maximum transfection efficiency and cell survival. The
combinations of cell solutions NHEM or T and nucleofector
programmes A-24 or U-20 produced the best results. We
compared nucleofection with two commercially available lipid-
based gene transfer systems, effectene and lipofectamine 2000
using a green fluorescent protein reporter vector. Nucleofection
demonstrated a 3- to 40-fold improvement in transfection
efficiency when compared with the lipid-based counterparts.
Nucleofection was also superior in transfecting small-interfering
RNA (siRNA) as determined by Western blot analysis. Lastly, we
applied nucleofection to the simultaneous transfection of a p53-
dependent luciferase plasmid and p53-siRNA. Experiments using
dual transfection showed knockdown of p53 expression and
silencing of the reporter plasmid. In conclusion, nucleofection is
highly effective for the transfer of nucleic acid substrates, singly or
in combination, into human melanoma cell lines.
Key words: co-transfection – gene transfer – melanoma –
nucleofection
Please cite this paper as: Nucleofection is a highly effective gene transfer technique for human melanoma cell lines. Experimental Dermatology 2008; 17:
405–411.
Introduction
Over the past decade, gene delivery systems have been
increasingly used to study and control gene expression.
Transfection of nucleic acid substrates has provided means
to upregulate gene expression, study transcriptional and
post-transcriptional regulation of various genes and gene
products, and downregulate expression of desired targets
(1). Non-viral approaches to gene transfer include those
mediated by chemical means, such as calcium phosphate,
DEAE dextran, and cationic lipo- or polysomes. Physical
techniques such as electroporation, hydroporation, ultra-
sound, and microinjection have also been used (1). Direct
injection, including the use of the ‘gene gun’, into whole
tissues such as muscle (1) and human skin has also been
performed (2) While some cells are easy to transfect,
melanoma cells, in particular, have remained difficult to
transfect with suitable efficiency. As an example, liposome-
mediated gene transfer yielded only 15% DNA delivery in a
murine melanoma cell line and 8% in a human melanoma
cell line. Moreover, the level of transgene expression in the
latter was undetectable (3). Despite the efforts to optimize
nucleic acid delivery, particularly with lipid-based delivery
systems or electroporation (4–8), these non-viral strategies
have not been widely successful in melanoma cells.
In contrast, viral vectors have been used successfully for
transfection of a wide variety of cell types, including mela-
noma. The use of lentivirus, in particular, resulted in high-
efficiency gene transduction in melanocytes and melanoma
cells and was an improvement over adenovirus- and retro-
viral-based vectors (9). An interesting recent report utilized
a retroviral vector which encoded the Cre recombinase to
DOI:10.1111/j.1600-0625.2007.00687.x
www.blackwellpublishing.com/EXDMethods
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411 405
remove an experimentally transfected SV-40 large T antigen
gene from melanocytes (10). This ‘reversible transfection’
of melanocytes with oncogenic SV-40 large T antigen
resulted in the short-term proliferation of melanocytes to
generate a large number of cells for treating experimentally
induced vitiligo. Once the cells were infected with the ret-
rovirus encoding the Cre recombinase, the SV-40 sequences
were excised from the melanocyte genomes, resulting in
non-transformed cells that could be transplanted into
experimental animals, and functioned to restore pigment to
the vitiliginous areas. While this is an exciting development
in melanocyte biology, the use of retroviruses generally suf-
fers from disadvantages such as the potential for insertional
mutagenesis, the time needed to construct vectors, and the
potential health and safety risks for laboratory personnel
(11–13). In addition, viral-based vectors are not suitable
for transient transfections. Studies of melanoma gene
expression have therefore been hampered by the lack of
effective and reproducible methods of gene transfer.
Nucleofection is a newer, non-viral gene delivery tech-
nology designed to expand upon the principles of electro-
poration for primary cells and hard-to-transfect cell lines.
Unlike traditional electroporation, nucleofection combines
cell-specific electrical parameters and Nucleofector Solu-
tion� (Amaxa AG, Cologne, Germany) to deliver genetic
material, including DNA, small-interfering RNA (siRNA),
and oligonucleotides directly to the nucleus. In doing so,
transfection is independent of cell division, leading to
increased efficiency. This method has already been success-
fully used in a number of cell types including keratinocytes
(14), human bone marrow-derived stem cells (15), endo-
thelial cells (16), glioblastoma cells (17), and melanocytes
(18). In this paper, we demonstrate that nucleofector tech-
nology can be successfully applied to many human mela-
noma cell lines for the efficient and simultaneous delivery
of DNA and siRNA, with results superior to that of com-
mercially available lipid-based transfection systems. More
efficient transfer of nucleic acid substrates into melanoma
cell lines may help to facilitate research efforts focusing on
the regulation of gene expression.
Methods
Cell cultureThirteen melanoma cell lines (SK-MEL 19, SK-MEL 23,
SK-MEL 29, SK-MEL 31, SK-MEL 85, SK-MEL 94,
SK-MEL 100, SK-MEL 103, SK-MEL 147, SK-MEL 173,
SK-MEL 187, SK-MEL 192, and SK-MEL 197) were a gift
of Dr Alan Houghton (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA). The cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Cambrex,
East Rutherford, NJ, USA) supplemented with 10%
foetal calf serum (Gibco, Grand Island, NY, USA), 2.0 mM
l-glutamine (ATCC, Manassas, VA, USA), 50 U ⁄ ml peni-
cillin, and 50 lg ⁄ ml streptomycin. The cells were passaged
twice weekly for maintenance in logarithmic growth phase.
Plasmids and siRNAThe pRSV-lacZ plasmid encoding the Escherichia coli
b-galactosidase reporter gene was a kind gift of Dr Susan
Logan (New York University School of Medicine, New
York, NY, USA). Green fluorescent protein (GFP) was
expressed using the pmaxGFP plasmid (Amaxa, Cologne,
Germany), derived from the copepod Potellina sp. Plasmids
were amplified in the DH5a strain of E. coli and purified
using the Qiagen EndoFree Plasmid Maxi Kit (Qiagen,
Valencia, CA, USA).
The hdm2luc01 firefly luciferase reporter plasmid was a
kind gift of Dr Jeremy P. Blaydes (University of Southamp-
ton, UK) and has been previously described (19). The
plasmid contains the p53-responsive P2 promoter of the
HDM2 gene. The pRL-TK reporter plasmid (Promega,
Madison, WI, USA), which produces low-level, constitutive
expression of Renilla luciferase, was used as an internal
control.
The siRNA directed against human p53 was designed
and synthesized by Qiagen. The sequences of the siRNA
used are as follows: p53-siRNA-1: 5¢-GGA AAU UUG CGU
GUG GAG U-3¢ and 5¢-ACU CCA CAC GCA AAU UUC
C-3¢. Non-silencing siRNA was also purchased from Qia-
gen. The sequences of the control siRNA used were
5¢-UUC UCC GAA CGU GUC ACG U-3¢ and 5¢-ACG
UGA CAC GUU CGG AGA A-3¢.
NucleofectionCells were nucleofected using materials supplied in the
Amaxa Cell Line Optimization Nucleofector Kit�(Amaxa). For nucleofection of reporter plasmids, mela-
noma cells were grown to a confluence of 70–80%. Follow-
ing trypsinization for 10 min, 2 · 106 cells were suspended
in either 100 ll of Cell Line Nucleofector Solution T, R, or
V or melanocyte-specific NHEM� solution (Amaxa) in an
Amaxa-certified cuvette.
To determine optimal nucleofection conditions for mela-
noma cell lines, 2 lg of pRSV-lacZ was used as a reporter,
added into each cell suspension and pulsed with the pro-
grammes described in the manufacturer’s protocol for cell
line optimization. Each programme differs in the intensity
and length of electrical pulsation; and the combination of a
selected Nucleofector Solution and programme define the
optimal nucleofection parameters. For experiments to eval-
uate expression of GFP, 2 lg of pmaxGFP was mixed into
the cell suspension, and nucleofection was performed using
the optimal conditions already established for each cell line.
The negative control did not have a reporter plasmid added
to the cuvette prior to pulsation.
Han et al.
ª 2008 The Authors
406 Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411
For experiments to nucleofect siRNA, 2 · 106 SK-MEL
19 cells were suspended in Cell Line Nucleofector Solution
R and mixed with 10 lg of either nonsense ⁄ scrambled
siRNA or p53-siRNA-1. The final volume did not exceed
120 ll. The solution was then pulsed with the T-20 nucleo-
fector programme.
For experiments co-transfecting DNA and siRNA,
2 · 106 cells were mixed with 0.2 lg of hdm2luc01 and
0.01 lg of prL-TK in Cell Line Nucleofector Solution
NHEM or R, for SK-MEL 100 or 173 cells, respectively,
and 10 lg of either nonsense ⁄ scrambled siRNA or p53-siR-
NA-1. The final volume did not exceed 120 ll. The solu-
tion was then pulsed with the appropriate programme,
A-24 for SK-MEL 100 cells or T-20 for SK-MEL 173 cells.
Immediately following pulsation, 500 ll of pre-warmed
Roswell Park Memorial Institute (RPMI) 1640 (Sigma, St
Louis, MO, USA) was added to each cuvette. (RPMI media
was used in lieu of standard culture medium, as its lower
calcium concentration facilitates membrane recovery from
the nucleofection procedure.) The cells were transferred to
a 1.5-ml Eppendorf tube and incubated at 37�C. After
10 min, the nucleofected cells were transferred to a
24-well plate containing fresh, pre-warmed DMEM
(0.5 · 106 cells ⁄ well) and maintained at 37�C.
Lipid-based transfectionsThe SK-MEL 19, 173, and 197 cells were transfected using
effectene (Qiagen) or lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). For transfection using effectene,
5 · 104 cells were plated onto a 24-well plate and grown
to a confluence of 50%. Transfection conditions were
optimized following the manufacturer’s specifications and
comprise the following: 0.2 lg of either pmaxGFP or
p53-siRNA transfected using a ratio of nucleic acid to lipo-
fection reagent of 1:50. For transfection with lipofectamine
2000, 0.75 · 105 cells were plated onto a 24-well plate and
grown to a confluence of 90%. Optimized conditions con-
sisted of 0.8 lg of either pmaxGFP or p53-siRNA transfect-
ed with a ratio of nucleic acid to lipofection reagent of 1:5.
All transfections were carried out in triplicate. All experi-
ments were performed at least twice.
Detection of p53Detection of p53 protein was accomplished using Western
blotting. Cells were lysed 48 h following transfection using
Laemmli’s sample buffer (BioRad, Hercules, CA, USA).
Fifty micrograms of cell lysate was fractionated using a
5–15% SDS–polyacrylamide gel (BioRad) and electropho-
retically transferred to a nitrocellulose membrane (What-
man, Brentford, Middlesex, UK). The membrane was
blocked with a solution of 8% non-fat milk in phosphate-
buffered saline (PBS) and 0.05% Tween-20 (Cambrex) for
2 h. The blocking solution was changed, and the
membrane incubated overnight, rocking at 4�C with the
primary antibody directed against human p53 (Ab-6,
1:1000; Oncogene, Cambridge, MA, USA). Following three
washes with a solution of PBS and 0.05% Tween-20, the
membrane was incubated, rocking at room temperature
for 1 h with the anti-mouse horseradish peroxidase
(HRP) secondary antibody (1:3000; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Proteins were visualized
on an autoradiography film (LabScientific, Inc., Living-
ston, NJ, USA) using the SuperSignal West Pico chemilu-
minescent system (Pierce, Rockford, IL, USA). Equal
loading of lanes was verified using anti-Ran, (C-20, 1:100;
Santa Cruz Biotechnology) as a primary antibody with
anti-goat HRP secondary antibody (1:3000).
Detection of b-galactosidase activityEfficiency of pRSV-lacZ transfection was detected 24 h
post-nucleofection by measuring b-galactosidase activity
with the b-Gal Staining Kit (Invitrogen). The manufac-
turer’s protocol was followed for the assay. Cells staining
blue after 2 h were considered to be positive for b-galacto-
sidase expression. Cells were visualized at 100 · magnifica-
tion using an Olympus IX 70 microscope (Olympus
Corporation, Tokyo, Japan). Nucleofection efficiency was
calculated by taking the proportion of blue cells when com-
pared with the total number of cells in the field. Ten fields
were counted and the mean nucleofection efficiency calcu-
lated for each cell line. Cell survival after nucleofection
was estimated by comparing the number of viable cells
that underwent nucleofection with the number of control
cells plated at the same time, which did not undergo
nucleofection.
Detection of GFP expressionPlates were inspected for expression of GFP 24 h post-
transfection using a compound microscope equipped with
a Nikon Epi-Fluorescence Attachment (Nikon Eclipse
TS100; Nikon Corporation, Japan). Images were observed
and captured using both a 40 · and 100 · objective
(Nikon Digital Camera DXM1200F). Images of each sec-
tion were visualized using both light and fluorescence
microscopy with the same compound microscope. The
proportion of fluorescent cells to total cells was calculated
as the estimated transfection efficiency.
Detection of luciferase activityForty-eight hours following nucleofection, cells were har-
vested and luminescence from both the firefly and Renilla
reporters was determined with the dual luciferase reporter
system following the manufacturer’s instructions. Lumines-
cence measurements were taken with the Berthold Lumat
LB9507 luminometer (Berthold, Oak Ridge, TN, USA).
Relative luminescence units (RLU) are defined as the ratio
Nucleofection of melanoma cells
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411 407
between firefly and Renilla luciferase. All nucleofections
were performed in triplicate.
Results
To determine the optimal nucleofection conditions yielding
the greatest efficiency and the lowest cell mortality, cells
from three melanoma cell lines (SK-MEL 19, 103, and 173)
were initially tested. Each cell line was tested using each of
the four Nucleofector Solutions (R, T, V, and NHEM),
using various electrical parameters (‘programmes’) as rec-
ommended by the manufacturer. Nucleofection efficiency
was estimated using a colorimetric b-galactosidase assay.
Based on the results of initial experiments, an additional
round(s) of optimization was performed by testing various
programmes in combination with the solution that pro-
duced the best results in the initial experiments. The spe-
cific programmes tested were based on advice from the
manufacturer. For example, Table 1 shows the results of
the optimization for line SK-MEL 19. The results of the
initial experiments using programme T-20 with solutions
T, R, or V are shown in panel A of Table 1. As these
parameters did not produce satisfactory results, solution
NHEM-Neo was tried in the subsequent experiment (panel
B of Table 1), and programmes T-20, U-20, and A-24 were
used. The best result was obtained with the programme
U-20, so an additional round of optimization was per-
formed using solution NHEM-Neo and various pro-
grammes of the ‘U’ series (panel C of Table 1). For this
line, the best combination of efficiency and cell viability
was obtained with programmes U-20 and U-22. Similar
experiments were carried out for other cell lines. An
example of nucleofection of the pRSV-lacZ plasmid for cell
lines SK-MEL 19, 94, and 173 is shown in Fig. 1.
For the SK-MEL 19, 94, and 173 cell lines, the NHEM,
T, or R Nucleofector Solutions in combination with pro-
grammes U-20, T-20, or A-24 demonstrated the greatest
nucleofection efficiencies. These results established a guide-
line to evaluate the optimal conditions for a larger set of
melanoma cell lines. In total, nucleofection optimization
experiments were performed on all 13 lines available in the
laboratory, and were successful for all lines tested. The final
nucleofection conditions and efficiencies for each cell line
are summarized in Table 2. Nucleofection efficiencies ran-
ged from a low of 20% in SK-MEL 187 to a high of 90%
in SK-MEL 94. Cell viability following nucleofection was
acceptable with 50–80% of cells remaining viable 48 h fol-
lowing the procedure. Solutions NHEM and T were very
effective, with seven cell lines optimally nucleofected using
Solution T, five using Solution NHEM, and one using
Solution R. Two programmes – U-20 and A-24 – emerged
as the most effective for nucleofection, and these were the
optimal programmes in 12 of the 13 cell lines.
Table 1. Optimization of nucleofection conditions for SK-MEL 19
Cell line Solution Programme
Efficiency
(%)
Mortality
(%)
A
SK-MEL 19 T T-20 <5 30
R T-20 <3 30
V T-20 <3 30
B
SK-MEL 19 NHEM-Neo T-20 20–30 80
NHEM-Neo U-20 50–60 80
NHEM-Neo A-24 <10 50
C
SK-MEL 19 NHEM-Neo U-11 10 50
NHEM-Neo U-14 20–30 60
NHEM-Neo U-15 10–15 60
NHEM-Neo U-16 5–10 50
NHEM-Neo U-17 20–30 50
NHEM-Neo U-20 70–80 40–50
NHEM-Neo U-22 70–80 40–50
Figure 1. Nucleofection of melanoma cell lines using pRSV-lacZ.
SK-MEL 19, 94, and 173 cells were nucleofected with pRSV-lacZ and
analysed 24 h following transfection. Nucleofection of the reporter
plasmid was detected using b-galactosidase. Cells expressing the
plasmid stain blue. Magnification is at 100·.
Table 2. Summary of optimized nucleofection conditions for
various melanoma cell lines
Cell line
Cell
solution Programme
Efficiency
(%)
Mortality
(%)
SK-MEL 19 NHEM U-20 70–80 40–50
SK-MEL 29 NHEM U-20 30–40 50
SK-MEL 85 T A-24 >80 20
SK-MEL 94 NHEM U-20 80–90 40–50
SK-MEL 100 NHEM A-24 50 20
SK-MEL 103 T A-24 50 30
SK-MEL 147 T U-20 50–60 30
SK-MEL 173 R T-20 80 20–30
SK-MEL 187 T U-20 20–30 40
SK-MEL 192 T A-24 30–40 50
SK-MEL 197 NHEM U-20 >80 <5
SK-MEL 23 T U-20 40–60 30–40
SK-MEL 31 T A-24 40 20
Han et al.
ª 2008 The Authors
408 Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411
Transfection using nucleofection was compared with
lipid-based gene delivery systems. Cells from three mela-
noma cell lines, SK-MEL 19, 173, and 197 were transfected
with pmaxGFP using the optimized conditions for nucleo-
fection, effectene, or lipofectamine 2000. The results in
Fig. 2 demonstrate significantly greater fluorescence with
nucleofection in SK-MEL 19 and 197 cells when compared
with transfection with effectene and lipofectamine. Similar
results were obtained for SK-MEL 173 cells (data not
shown). The overall efficiency of gene transfer was esti-
mated to be 80% for nucleofection in all three cell lines. In
contrast, transfection with effectene resulted in estimated
efficiencies of 2% in SK-MEL 19 cells, 5% in SK-MEL 173
cells, and 1% in SK-MEL 197 cells. Transfection with lipo-
fectamine 2000 yielded similar results in SK-MEL 19 cells,
but results were improved for SK-MEL 173 and 197 cells,
with estimated efficiencies of 25% and 10%, respectively.
Mortality of SK-MEL 173 and 197 cells for nucleofection
remained low and were similar to those listed in Table 2.
Of note, mortality of SK-MEL 19 cells was greater using
nucleofection when compared with lipid-based transfection,
but the net number of transfected cells was substantially
greater than either lipid-based system.
A comparison of these techniques was also made for the
transfer of siRNA. SK-MEL 19 cells were transfected with
siRNA directed against p53 using optimized conditions for
nucleofection, effectene, or lipofectamine 2000. Control
cells were transfected with nonsense ⁄ scrambled siRNA.
Forty-eight hours after transfection, cells were lysed, and
detection of p53 protein was accomplished using Western
blotting (Fig. 3). In the right panel, a significant reduction
in p53 expression was observed in those cells subjected to
nucleofection when compared with control cells. Transfec-
tion with lipofectamine 2000 (middle panel) resulted in a
partial reduction of p53. Transfection with effectene (left
panel) failed to produce a detectable reduction in p53
levels.
One of the major advantages of nucleofector technology
is the ability to deliver DNA and siRNA to cell nuclei using
a single nucleofection condition. To test the co-transfection
capabilities of nucleofection, SK-MEL 173 and 100 cells
were nucleofected with p53-siRNA (or nonsense ⁄ scrambled
siRNA) plus plasmid DNA encoding the HDM2 promoter
driving a luciferase reporter gene. The protocol followed
was identical to those used for single agent nucleofection
(Table 2).
As seen in Fig. 4, the RLU for SK-MEL 173 cells
co-transfected with hdm2luc01 and nonsense ⁄ scrambled
p53-siRNA was 105.6 ± 9.9. When SK-MEL 173 cells were
co-transfected with p53-siRNA and hdm2luc01, however,
the RLU fell to 20.5 ± 2.3. Similar results were observed
for SK-MEL 100 cells. These results demonstrate the suc-
cessful knockdown of p53 through nucleofection of siRNA,
thereby suppressing the transcription of the p53-responsive
reporter plasmid. In addition, these findings show that
simultaneous transfection of plasmid DNA and siRNA are
readily accomplished using nucleofection.
Discussion
Despite great investigative advances afforded by the advent
of gene transfer technologies, these methods have not been
applied widely to the study of melanoma biology. Efforts
to conduct transgene studies of melanoma have largely
been hampered by the lack of efficient transfection meth-
ods, especially among non-viral vectors (9). In this paper,
we demonstrate that nucleofector technology is a highly
effective method for transfecting nucleic acid substrates
individually or in combination into human melanoma cell
lines.
(a)
SK-MEL 19 SK-MEL 197
(b)
(c)
Figure 2. Comparison of GFP expression 24 h following transfection
with nucleofector or lipid-based gene transfer systems. SK-MEL 19 and
197 cells were transfected using nucleofection (row a), lipofectamine
2000 (row b), or effectene (row c). Images of the right-hand panel for
each cell line were captured under fluorescence microscopy and show
cells in a representative field expressing GFP. Images of the left-hand
panel for each cell line were captured under simultaneous light and
fluorescence microscopy and demonstrate the total number of cells in
the field. Bright white cells are those expressing GFP. Magnification is
at 100·, except for SK-MEL 197 rows b and c, which are at 40·.
Figure 3. Western blot comparing p53 protein expression following
siRNA transfection using three techniques. SK-MEL 19 cells were
transfected with p53-siRNA using effectene, lipofectamine 2000, and
nucleofection. Transfection with nonsense ⁄ scrambled siRNA was used
as a negative control. Forty-eight hours following transfection, cells
were harvested for Western blotting for p53 expression. The protein
Ran was used to confirm equal protein loading of each lane. c. siRNA,
control siRNA.
Nucleofection of melanoma cells
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411 409
In order to obtain the best combination of transfection
efficiency and cell survival, the optimal nucleofection con-
ditions must be determined. A flow chart of the optimiza-
tion strategy we employed is shown in Fig. 5. In general,
optimization follows a stepwise process, in which the first
step is the determination of the appropriate nucleofector
solution; this is followed by testing various electrical
parameters until the optimal combination of transfection
efficiency and low mortality is determined. Whereas the
manufacturer Amaxa has optimized conditions for human
melanocyte cultures and for two human and two mouse
melanoma cell lines, we successfully transfected 13 different
human melanoma cell lines. Through our rounds of opti-
mization experiments, we found that the conditions that
yielded the best results in 12 of the cell lines were Nucleo-
fector Cell Line Solution NHEM or T in combination with
programme U-20 or A-24 (Table 2). These two solutions
and programmes may therefore serve as the basis for initial
experiments nucleofecting melanoma cell lines for those
investigators who are using the Amaxa nucleofector system
for the first time. These combinations, however, should not
be considered a substitute for conducting a full series of
optimization experiments following the manufacturer’s
protocol to determine optimal nucleofection conditions for
each cell line. This is highlighted by the finding that in the
SK-MEL 173 cell line, optimal nucleofection occurred with
a combination of Solution R and programme T-20, in con-
trast to the other 12 cell lines. Conditions for human mela-
nocyte cultures and other melanoma cell lines optimized by
Amaxa are listed in Table 3. We have also listed three
human melanoma lines in which nucleofection was used to
transfer siRNA directed against BRAF (20).
Figure 4. Results of co-transfection of siRNA and plasmid DNA as
measured by luciferase activity. SK-MEL 173 and 100 cells were
co-transfected with p53-siRNA and hdm2luc01 using nucleofector
technology. The presence of p53 is required for activation of the
luciferase reporter plasmid. Nucleofection of nonsense ⁄ scrambled siRNA
with hdm2luc01 served as the negative control. Co-transfection with
functional p53-siRNA resulted in a significant decrease in luciferase
activity for both cell lines. c. siRNA, control siRNA; RLU, relative
luminescence units.
Step 1 – Select the best Nucleofection SolutionTransfect the cell line of interest using program T-20 and each of the Nucleofector
solutions. The solution which yields the highest combination of transfection efficiencyand lowest mortality is used for the next step
Step 2 – Select the optimal Electrical Parameters Transfect the cell line using selected Nucleofector solution and each of the three
programs, U-20, T-20 and A-24. The condition which results in the highest combinationof transfection efficiency and lowest mortality is used for the next step.
Step 3 – Optimize the Conditions Perform additional transfections using the selected Nucleofector solution with severalprograms related to the program selected in Step 2. The goal is to further maximize
efficiency and minimize mortality. The company can help select the appropriateprograms to test.
Figure 5. Flow chart of nucleofection optimization strategy. The chart
outlines the general principles and steps taken to optimize the
transfection of cell lines using the nucleofection method.
Table 3. Summary of available nucleofector
conditions
Cell line Programme Solution Substrate
Efficiency
(%)
Viable
cells (%)
Analysis
method
Normal human
melanocytes1
U-24 NHEM 2.5 lg eGFP 55 ± 8 55–60 n ⁄ a
A-3751 X-001 V 2 lg maxGFP 72 ± 2 97 FACS
A-20581 X-001 C 2 lg maxGFP 81 ± 2 94 ± 1 FACS
B16-F01 P-031 R 2 lg maxGFP 84 ± 1 90 ± 1 FACS
B16-F101 P-020 V 2 lg maxGFP 91 ± 6 96 ± 1 FACS
1205Lu2 K-017 R 100 pmol siRNA
anti-BRAF
90 Western blot
C81612 K-017 R 100 pmol siRNA
anti-BRAF
90 Western blot
UACC9032 K-017 R 100 pmol siRNA
anti-BRAF
90 Western blot
1Optimized conditions by Amaxa.2From Sharma et al. (20).
Han et al.
ª 2008 The Authors
410 Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411
Nucleofection was more effective at gene transfer than
two commercially available lipid-based systems in experi-
ments transfecting plasmid DNA or siRNA. In terms of the
latter, suppression of gene function by mediating degrada-
tion of target mRNA has numerous research and therapeu-
tic implications. Recent studies in the field have focused on
using siRNA to silence oncogenes or other genes contribut-
ing to melanoma development or progression (21–23), but
given the difficulty in transfecting melanoma cells with
acceptable efficiencies, no standard procedure has emerged.
We found that nucleofection was a highly useful technique
to transfect DNA, siRNA, or both simultaneously in a sin-
gle step as demonstrated in Fig. 4. This versatility offers
significant opportunities to manipulate in vitro systems.
Another advantage of this technology is its ease of use.
Experimental procedures consisting of preparing the sam-
ples, pulsing the solution, and plating the newly nucleofect-
ed cells can be accomplished in less than 20 min.
Furthermore, because the nucleic acids are delivered
directly to the cell nucleus, cell division is not required for
substrate incorporation into the nucleus. This reduces the
delay between nucleofection and expression.
The limited drawbacks to using this system include
decreased cell survival in some lines when compared with
lipid-based gene delivery following nucleofection. However,
given the significantly higher transfection efficiency, the
increased mortality is not a major limitation in melanoma
cell lines. Another disadvantage is the high cost of this
technology in comparison to other gene transfer systems.
In conclusion, nucleofector technology enables the highly
efficient transfection of melanoma cells, which have tradi-
tionally been resistant to gene transfer using other non-
viral methods. With the ability to transfer DNA, siRNA, or
both simultaneously, this technology offers great promise
in aiding future investigative efforts in the field of
melanoma.
References
1 Dean D A. Nonviral gene transfer to skeletal, smooth, and cardiac
muscle in living animals. Am J Physiol Cell Physiol 2005: 289:
C233–C245.
2 Tuting T, Storkus W J, Falo L D, Jr. DNA immunization targeting the
skin: molecular control of adaptive immunity. J Invest Dermatol
1998: 111: 183–188.
3 Reimer D L, Kong S, Bally M B. Analysis of cationic liposome-
mediated interactions of plasmid DNA with murine and human
melanoma cells in vitro. J Biol Chem 1997: 272: 19480–19487.
4 Cemazar M, Pavlin D, Kranjc S, Grosel A, Mesojednik S, Sersa G.
Sequence and time dependence of transfection efficiency of electri-
cally-assisted gene delivery to tumors in mice. Curr Drug Deliv
2006: 3: 77–81.
5 Cemazar M, Sersa G, Wilson J et al. Effective gene transfer to solid
tumors using different nonviral gene delivery techniques: electropo-
ration, liposomes, and integrin-targeted vector. Cancer Gene Ther
2002: 9: 399–406.
6 Dong W, Jin G H, Li S F, Sun Q M, Ma D Y, Hua Z C. Cross-linked
polyethylenimine as potential DNA vector for gene delivery with
high efficiency and low cytotoxicity. Acta Biochim Biophys Sin
(Shanghai) 2006: 38: 780–787.
7 Reynier P, Briane D, Coudert R et al. Modifications in the head
group and in the spacer of cholesterol-based cationic lipids promote
transfection in melanoma B16-F10 cells and tumours. J Drug Target
2004: 12: 25–38.
8 Yang J P, Huang L. Overcoming the inhibitory effect of serum on
lipofection by increasing the charge ratio of cationic liposome to
DNA. Gene Ther 1997: 4: 950–960.
9 Dunlap S, Yu X, Cheng L, Civin C I, Alani R M. High-efficiency
stable gene transduction in primary human melanocytes using
a lentiviral expression system. J Invest Dermatol 2004: 122: 549–
551.
10 Ying W, Fei H, Jun D, Xi-chuan Y, Bai-yu Z, Qing-yi Y. Reversible
transfection of human melanocytes mediated by Cre ⁄ loxP site-spe-
cific recombination system and SV40 large T antigen. Exp Dermatol
2007: 16: 437–444.
11 Liu F, Shollenberger L M, Huang L. Non-immunostimulatory nonviral
vectors. FASEB J 2004: 18: 1779–1781.
12 Muruve D A. The innate immune response to adenovirus vectors.
Hum Gene Ther 2004: 15: 1157–1166.
13 Scanlon K J. Cancer gene therapy: challenges and opportunities.
Anticancer Res 2004: 24: 501–504.
14 Distler J H, Jungel A, Kurowska-Stolarska M et al. Nucleofection: a
new, highly efficient transfection method for primary human kerati-
nocytes*. Exp Dermatol 2005: 14: 315–320.
15 Aluigi M, Fogli M, Curti A et al. Nucleofection is an efficient
nonviral transfection technique for human bone marrow-derived
mesenchymal stem cells. Stem Cells 2006: 24: 454–461.
16 Thiel C, Nix M. Efficient transfection of primary cells relevant for
cardiovascular research by nucleofection. Methods Mol Med 2006:
129: 255–266.
17 Hagemann C, Meyer C, Stojic J et al. High efficiency transfection of
glioma cell lines and primary cells for overexpression and RNAi
experiments. J Neurosci Methods 2006: 156: 194–202.
18 Westbroek W, Lambert J, Bahadoran P et al. Interactions of human
Myosin Va isoforms, endogenously expressed in human melano-
cytes, are tightly regulated by the tail domain. J Invest Dermatol
2003: 120: 465–475.
19 Phelps M, Darley M, Primrose J N, Blaydes J P. p53-independent
activation of the hdm2-P2 promoter through multiple transcription
factor response elements results in elevated hdm2 expression in
estrogen receptor alpha-positive breast cancer cells. Cancer Res
2003: 63: 2616–2623.
20 Sharma A, Trivedi N R, Zimmerman M A, Tuveson D A, Smith C D,
Robertson G P. Mutant V599EB-Raf regulates growth and vascular
development of malignant melanoma tumors. Cancer Res 2005:
65: 2412–2421.
21 Chen X, Lin J, Kanekura T et al. A small interfering CD147-targeting
RNA inhibited the proliferation, invasiveness, and metastatic activity
of malignant melanoma. Cancer Res 2006: 66: 11323–11330.
22 Li S, Dong W, Zong Y et al. Polyethylenimine-complexed plasmid
particles targeting focal adhesion kinase function as melanoma
tumor therapeutics. Mol Ther 2007: 15: 515–523.
23 Nakai N, Kishida T, Shin-Ya M et al. Therapeutic RNA interference
of malignant melanoma by electrotransfer of small-interfering RNA
targeting Mitf. Gene Ther 2007: 14: 357–365.
Nucleofection of melanoma cells
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Munksgaard, Experimental Dermatology, 17, 405–411 411